Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 93

1.

Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study.

Brown DM, Campochiaro PA, Bhisitkul RB, Ho AC, Gray S, Saroj N, Adamis AP, Rubio RG, Murahashi WY.

Ophthalmology. 2011 Aug;118(8):1594-602. doi: 10.1016/j.ophtha.2011.02.022.

PMID:
21684606
2.

Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study.

Campochiaro PA, Heier JS, Feiner L, Gray S, Saroj N, Rundle AC, Murahashi WY, Rubio RG; BRAVO Investigators.

Ophthalmology. 2010 Jun;117(6):1102-1112.e1. doi: 10.1016/j.ophtha.2010.02.021. Epub 2010 Apr 15.

PMID:
20398941
3.

Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study.

Brown DM, Campochiaro PA, Singh RP, Li Z, Gray S, Saroj N, Rundle AC, Rubio RG, Murahashi WY; CRUISE Investigators.

Ophthalmology. 2010 Jun;117(6):1124-1133.e1. doi: 10.1016/j.ophtha.2010.02.022. Epub 2010 Apr 9.

PMID:
20381871
4.

Intravitreal ranibizumab (Lucentis) for branch retinal vein occlusion-induced macular edema: nine-month results of a prospective study.

Rouvas A, Petrou P, Ntouraki A, Douvali M, Ladas I, Vergados I.

Retina. 2010 Jun;30(6):893-902. doi: 10.1097/IAE.0b013e3181cd4894.

PMID:
20531142
5.

Intravitreal ranibizumab for macular edema secondary to central retinal vein occlusion.

Risard SM, Pieramici DJ, Rabena MD, Basefsky JC, Avery RL, Castellarin AA, Nasir MA, See RF, Couvillion SS.

Retina. 2011 Jun;31(6):1060-7. doi: 10.1097/IAE.0b013e3181fbce76.

PMID:
21283055
6.

Antagonism of vascular endothelial growth factor for macular edema caused by retinal vein occlusions: two-year outcomes.

Campochiaro PA, Hafiz G, Channa R, Shah SM, Nguyen QD, Ying H, Do DV, Zimmer-Galler I, Solomon SD, Sung JU, Syed B.

Ophthalmology. 2010 Dec;117(12):2387-2394.e1-5. doi: 10.1016/j.ophtha.2010.03.060. Epub 2010 Jul 13.

PMID:
20630595
7.

Ranibizumab for macular edema due to retinal vein occlusions: long-term follow-up in the HORIZON trial.

Heier JS, Campochiaro PA, Yau L, Li Z, Saroj N, Rubio RG, Lai P.

Ophthalmology. 2012 Apr;119(4):802-9. doi: 10.1016/j.ophtha.2011.12.005. Epub 2012 Feb 1.

PMID:
22301066
8.

Intravitreal ranibizumab for macular oedema secondary to retinal vein occlusion: a retrospective study of 34 eyes.

Puche N, Glacet A, Mimoun G, Zourdani A, Coscas G, Soubrane G.

Acta Ophthalmol. 2012 Jun;90(4):357-61. doi: 10.1111/j.1755-3768.2010.01913.x. Epub 2010 Jun 29.

9.

Efficacy of ranibizumab in patients with macular edema secondary to central retinal vein occlusion: results from the sham-controlled ROCC study.

Kinge B, Stordahl PB, Forsaa V, Fossen K, Haugstad M, Helgesen OH, Seland J, Stene-Johansen I.

Am J Ophthalmol. 2010 Sep;150(3):310-4. doi: 10.1016/j.ajo.2010.03.028. Epub 2010 Jun 29.

PMID:
20591399
10.

Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase III study.

Campochiaro PA, Brown DM, Awh CC, Lee SY, Gray S, Saroj N, Murahashi WY, Rubio RG.

Ophthalmology. 2011 Oct;118(10):2041-9. doi: 10.1016/j.ophtha.2011.02.038. Epub 2011 Jun 29.

PMID:
21715011
11.

Efficacy and safety of anti-vascular endothelial growth factor (VEGF) therapy with intravitreal ranibizumab (Lucentis) for naive retinal vein occlusion: 1-year follow-up.

Pece A, Isola V, Piermarocchi S, Calori G.

Br J Ophthalmol. 2011 Jan;95(1):56-68. doi: 10.1136/bjo.2009.174060. Epub 2010 Jul 3.

PMID:
20601660
12.

Randomized controlled trial of intravitreal ranibizumab versus standard grid laser for macular edema following branch retinal vein occlusion.

Tan MH, McAllister IL, Gillies ME, Verma N, Banerjee G, Smithies LA, Wong WL, Wong TY.

Am J Ophthalmol. 2014 Jan;157(1):237-247.e1. doi: 10.1016/j.ajo.2013.08.013. Epub 2013 Oct 7.

PMID:
24112635
13.

Improved vision-related function after ranibizumab for macular edema after retinal vein occlusion: results from the BRAVO and CRUISE trials.

Varma R, Bressler NM, Suñer I, Lee P, Dolan CM, Ward J, Colman S, Rubio RG; BRAVO and CRUISE Study Groups.

Ophthalmology. 2012 Oct;119(10):2108-18. doi: 10.1016/j.ophtha.2012.05.017. Epub 2012 Jul 18.

PMID:
22817833
14.

Intravitreal ranibizumab for macular edema secondary to retinal vein occlusion.

Kim M, Yu SY, Kim ES, Bae SH, Park JH, Yu HG, Kwak HW.

Ophthalmologica. 2012;227(3):132-8. doi: 10.1159/000334906. Epub 2011 Dec 29.

PMID:
22212151
15.

Ranibizumab for the treatment of macular edema associated with perfused central retinal vein occlusions.

Pieramici DJ, Rabena M, Castellarin AA, Nasir M, See R, Norton T, Sanchez A, Risard S, Avery RL.

Ophthalmology. 2008 Oct;115(10):e47-54. doi: 10.1016/j.ophtha.2008.06.021. Epub 2008 Aug 16.

PMID:
18708258
16.

Intravitreal ranibizumab (Lucentis) for treatment of central retinal vein occlusion: a prospective study.

Rouvas A, Petrou P, Vergados I, Pechtasides D, Liarakos V, Mitsopoulou M, Ladas I.

Graefes Arch Clin Exp Ophthalmol. 2009 Dec;247(12):1609-16. doi: 10.1007/s00417-009-1138-y. Epub 2009 Jul 16.

PMID:
19609550
17.

Ranibizumab for serous macular detachment in branch retinal vein occlusions.

Gallego-Pinazo R, Dolz-Marco R, Pardo-López D, Martínez-Castillo S, Lleó-Pérez A, Arévalo JF, Díaz-Llopis M.

Graefes Arch Clin Exp Ophthalmol. 2013 Jan;251(1):9-14. doi: 10.1007/s00417-012-2023-7. Epub 2012 Apr 25.

PMID:
22527327
18.

Monthly ranibizumab for nonproliferative macular telangiectasia type 2: a 12-month prospective study.

Charbel Issa P, Finger RP, Kruse K, Baumüller S, Scholl HP, Holz FG.

Am J Ophthalmol. 2011 May;151(5):876-886.e1. doi: 10.1016/j.ajo.2010.11.019. Epub 2011 Feb 19. Erratum in: Am J Ophthalmol. 2011 Jul;152(1):151.

PMID:
21334595
19.

Reading speed improvements in retinal vein occlusion after ranibizumab treatment.

Suñer IJ, Bressler NM, Varma R, Lee P, Dolan CM, Ward J, Colman S, Rubio RG.

JAMA Ophthalmol. 2013 Jul;131(7):851-6. doi: 10.1001/jamaophthalmol.2013.114.

PMID:
23699977
20.

Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1-year results from the phase 3 COPERNICUS study.

Brown DM, Heier JS, Clark WL, Boyer DS, Vitti R, Berliner AJ, Zeitz O, Sandbrink R, Zhu X, Haller JA.

Am J Ophthalmol. 2013 Mar;155(3):429-437.e7. doi: 10.1016/j.ajo.2012.09.026. Epub 2012 Dec 4.

PMID:
23218699

Supplemental Content

Support Center